Product image of Mikrobiel (Moxifloxacin) supplied by GNH India

Mikrobiel

Active Ingredient:
Moxifloxacin
Origin:
EU

Mikrobiel (Moxifloxacin)

Moxifloxacin, the active ingredient in Mikrobiel, is a fluoroquinolone antibiotic presented as an intravenous solution for intravenous use. It treats severe bacterial infections that require hospital‑based IV therapy, including pneumonia, sinusitis, skin‑structure and intra‑abdominal infections. It is indicated for patients who cannot take oral therapy and for infections caused by susceptible Gram‑negative and Gram‑positive organisms.

GNH India supplies Mikrobiel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to EU quality standards and provides reliable logistics for clinical use.

Manufacturer / TM Owner

Cooper Pharmaceuticals S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Moxifloxacin is employed to treat bacterial infections affecting several organ systems.

  • Community‑acquired bacterial pneumonia: effective eradication of susceptible pathogens causing lung infection.
  • Acute bacterial sinusitis: rapid resolution of sinus inflammation due to susceptible bacteria.
  • Complicated skin and skin‑structure infections: control of severe dermal infections resistant to oral therapy.
  • Complicated intra‑abdominal infections: treatment of mixed‑organism infections requiring IV antibiotics.
  • Severe bacterial infections requiring IV therapy: broad‑spectrum coverage for hospitalized patients with serious infections.

How It Works

  • Moxifloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. By binding to the enzyme‑DNA complex, it prevents the resealing of DNA strands, leading to bacterial cell death and a bactericidal effect against a wide range of Gram‑positive and Gram‑negative organisms.

Side Effects

Adverse reactions may occur with intravenous moxifloxacin therapy.

Common Side Effects

  • Nausea: mild to moderate upset stomach.
  • Diarrhea: loose stools, usually self‑limiting.
  • Headache: transient cranial discomfort.
  • Injection site pain: local discomfort at the infusion site.

Serious or Rare Side Effects

  • Tendon rupture: especially Achilles tendon, may occur without warning.
  • QT interval prolongation: risk of ventricular arrhythmias.
  • Severe allergic reactions: anaphylaxis, skin rash, or angioedema.
  • Clostridioides difficile infection: colitis due to disruption of gut flora.

Precautions & Warnings

Use of intravenous moxifloxacin requires careful clinical assessment.

  • Renal impairment: monitor renal function and adjust therapy as needed.
  • Hepatic impairment: use with caution in patients with liver disease.
  • History of tendon disorders: avoid use due to increased risk of tendon rupture.
  • Concomitant QT‑prolonging drugs: monitor ECG for arrhythmia risk.
  • Pregnancy and lactation: assess risk versus benefit before prescribing.
  • Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Moxifloxacin may interact with several medications; clinical monitoring is advised.

Major Interactions (Avoid)

  • Concurrent fluoroquinolones: increased risk of toxicity.
  • Systemic corticosteroids: heightened tendon rupture risk.
  • Other QT‑prolonging agents: additive risk of cardiac arrhythmias.
  • Warfarin: potential enhancement of anticoagulant effect.

Moderate Interactions (Monitor Closely)

  • Non‑steroidal anti‑inflammatory drugs: possible renal adverse effects.
  • Cyclosporine: increased nephrotoxicity risk.
  • Theophylline: may raise serum theophylline concentrations.
  • Rifampin: may reduce moxifloxacin plasma levels.

Frequently Asked Questions

Mikrobiel, containing the fluoroquinolone moxifloxacin, is indicated for severe bacterial infections that require intravenous therapy, such as community‑acquired pneumonia, acute bacterial sinusitis, complicated skin‑structure infections, complicated intra‑abdominal infections, and other serious infections where oral treatment is unsuitable.

Moxifloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes needed for DNA replication and transcription. By preventing these enzymes from resealing DNA strands, the drug causes bacterial DNA breakage and leads to rapid bacterial cell death.

The dosage of Mikrobiel is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal and hepatic function, and local antimicrobial guidelines. Only a qualified healthcare professional should set the exact dosing regimen.

Safety data for moxifloxacin in pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by the treating physician.

To request Mikrobiel, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Mikrobiel (moxifloxacin) offers a broader spectrum against both Gram‑positive and Gram‑negative organisms and has enhanced activity against atypical pathogens compared with older fluoroquinolones like ciprofloxacin. It also provides once‑daily dosing in many regimens, though safety considerations such as tendon and QT‑interval risks remain similar across the class.

Mikrobiel should be stored at 2 °C to 8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution to maintain stability and potency.

Mikrobiel is given as an intravenous infusion by a qualified healthcare professional. The infusion rate and duration are set by the prescriber, typically over a period of 30 to 60 minutes, and the medication is administered through a sterile IV line under aseptic conditions.

The most serious adverse events linked to intravenous moxifloxacin include tendon rupture (especially the Achilles tendon), QT‑interval prolongation leading to potentially life‑threatening arrhythmias, severe allergic reactions such as anaphylaxis, and Clostridioides difficile‑associated colitis.

Mikrobiel is contraindicated in patients with a known hypersensitivity to moxifloxacin or other fluoroquinolones, those with a history of tendon disorders related to fluoroquinolone use, and individuals taking other medications that significantly prolong the QT interval without appropriate monitoring.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Moxifloxacin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT